^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
lartesertib (M4076)
i
Other names: M4076, M-4076, M 4076
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
EMD Serono
Drug class:
ATM kinase inhibitor
Related drugs:
7d
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (clinicaltrials.gov)
P2, N=63, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial primary completion date: Sep 2025 --> Jun 2026
Trial primary completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
|
BRCA1 mutation • HRD
|
Zejula (niraparib) • tuvusertib (M1774) • lartesertib (M4076)
13d
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) (clinicaltrials.gov)
P1, N=120, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Apr 2026 --> Jan 2027 | Trial primary completion date: Apr 2026 --> Jan 2027
Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker
|
ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A)
|
ARID1A mutation
|
Bavencio (avelumab) • tuvusertib (M1774) • lartesertib (M4076)
4ms
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (clinicaltrials.gov)
P2, N=63, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Jan 2028 --> Jun 2026 | Trial primary completion date: Jan 2028 --> Sep 2025
Trial completion date • Trial primary completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
|
BRCA1 mutation • HRD
|
Zejula (niraparib) • tuvusertib (M1774) • lartesertib (M4076)
5ms
DNA Damage Sensing and TP53 Function as Modulators of Sensitivity to Calicheamicin-Based Antibody-Drug Conjugates for Acute Leukemia. (PubMed, Cancers (Basel))
These results support further evaluation of combination therapies with corresponding small-molecule inhibitors (currently pursued for therapy of other cancers) toward clinical testing as novel strategies to increase the efficacy of CLM-based ADCs such as GO and InO.
Journal • PARP Biomarker
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type
|
Besponsa (inotuzumab ozogamicin) • Mylotarg (gemtuzumab ozogamicin) • idasanutlin (RG7388) • AZD1390 • lartesertib (M4076)
9ms
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) (clinicaltrials.gov)
P1, N=120, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Recruiting --> Active, not recruiting
Enrollment closed • Checkpoint inhibition • IO biomarker
|
Bavencio (avelumab) • tuvusertib (M1774) • lartesertib (M4076)
9ms
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (clinicaltrials.gov)
P2, N=63, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Recruiting --> Active, not recruiting | N=130 --> 63
Enrollment closed • Enrollment change
|
Zejula (niraparib) • tuvusertib (M1774) • lartesertib (M4076)
11ms
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (clinicaltrials.gov)
P2, N=130, Recruiting, EMD Serono Research & Development Institute, Inc. | N=60 --> 130
Enrollment change
|
Zejula (niraparib) • tuvusertib (M1774) • lartesertib (M4076)
1year
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) (clinicaltrials.gov)
P1, N=123, Recruiting, EMD Serono Research & Development Institute, Inc. | N=72 --> 123
Enrollment change • Checkpoint inhibition • IO biomarker
|
Bavencio (avelumab) • tuvusertib (M1774) • lartesertib (M4076)
over1year
Discovery of a Novel and Potent Dual-Targeting Inhibitor of ATM and HDAC2 Through Structure-Based Virtual Screening for the Treatment of Testicular Cancer. (PubMed, Drug Des Devel Ther)
In vivo experiments exhibited that AMH-4 was more effective than lartesertib and vorinostat in inhibiting the growth of NTERA-2 cL.D1 xenograft tumors with low toxicity. Overall, these results suggest that AMH-4 is an effective and low toxicity candidate for the treatment of testicular germ cell tumors.
Journal
|
HDAC2 (Histone deacetylase 2)
|
Zolinza (vorinostat) • lartesertib (M4076)
almost2years
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (clinicaltrials.gov)
P2, N=60, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
Zejula (niraparib) • tuvusertib (M1774) • lartesertib (M4076)
2years
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (clinicaltrials.gov)
P2, N=60, Not yet recruiting, EMD Serono Research & Development Institute, Inc.
New P2 trial • Combination therapy
|
Zejula (niraparib) • tuvusertib (M1774) • lartesertib (M4076)
2years
Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) (clinicaltrials.gov)
P1, N=72, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Dec 2023 --> May 2026 | Trial primary completion date: Dec 2023 --> Mar 2026
Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • IO biomarker • Metastases
|
Bavencio (avelumab) • tuvusertib (M1774) • lartesertib (M4076)
Share via
